작성일 : 17-01-26
Article in Parkinson's Disease Study
 글쓴이 : 운영자
 

 

Article Cites HemogloBind™ in Parkinson’s Disease Study

 

 

MONMOUTH JUNCTION, NJ, January 24, 2017 -- BiotechSupport Group reports on a recent research article

describing the simplicity and efficiency of their hemoglobin depletion technologyfor improving the signal from

whole blood protein immunoblot analysis. Thecitation is:

 

Lahut, Suna, et al. "Blood RNA biomarkers in prodromal PARK4 and REM sleepbehavior disorder show role of

complexin-1 loss for risk of Parkinson'sdisease." Disease Models & Mechanisms (2017): dmm-028035.

http://dmm.biologists.org/lookup/doi/10.1242/dmm.028035

 

In this study, Parkinson’s disease progression is investigated through the accumulationand aggregation of the

lipid-binding SNARE complex component alpha-synuclein(SNCA) which underlies vulnerability and defines its

stages. The authorsstudied blood samples from a new large pedigree with SNCA geneduplication

(PARK4 mutation) , to identify effects of SNCA gain-of-function aspotential disease biomarkers. The article

states “For protein extraction fromthe EDTA tubes, 300 μl blood were lysed with equal amount of 1% SDS-RIPA

buffer[50 mM Tris-HCl  (pH 8.0), 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 1% Igepal CA-630(Sigma), 0.5%

sodium deoxycholate, 0.1% SDS,  1 mM PMSF and one tablet CompleteProtease Inhibitor Cocktail (Roche)] and

sonicated for 10 sec. The blood lysates were rotated at 4 °C for 30 min and centrifuged at 4 °C for 30 min.

Thesupernatants were depleted in hemoglobin content using a commercial kit(HemogloBind, Biotech) following

the manufacturer’s instructions”. After hemoglobin depletion, immunoblot analysis identified that PARK4 blood

showedupregulation of alpha-synuclein monomer, with no high molecular weightaggregates.

 

“Because of the large amount of hemoglobin in whole blood, itsvery exciting to see that HemogloBind™ can

reduce the presence of hemoglobinsufficient for such precise immunoblot analysis.” states Swapan Roy,

Ph.D.,President and Founder of Biotech Support Group.

For more information on HemogloBind™, visit:

http://www.biotechsupportgroup.com/HemogloBind-Hemoglobin-Depletion-From-Hemolyzed-p/h0145.htm

 

 

Contact:

Matthew Kuruc 732-274-2866, mkuruc@biotechsupportgroup.com

 

 

 

▣ 관련 페이지 ; Biotech Support Group